click below
click below
Normal Size Small Size show me how
N232-U2-ANTIDYSRHTH
ANTIDYSRHTHMIC DRUGS
| Question | Answer |
|---|---|
| WHAT ARE THE FOUR GROUPS OF ANTI-DYSRHTHMIC DRUGS | GROUP I-SODIUM CHANNEL BLOCKERS, GROUP II-BETA-BLOCKERS, GROUP III-POTASSIUM CHANNEL BLOCKERS AND GROUP IV-CALCIUM CHANNEL BLOCKERS |
| SODIUM CHANNEL BLOCKERS ARE GROUPED BASED ON THEIR EFFECTS ON WHAT PART OF THE ACTION POTENTIAL | REPOLARIZATION |
| GROUP I-A SODIUM CHANNEL BLOCKERS ACT BY | BLOCKING THE RAPID INFLUX OF NA+ INTO CARDIAC CELLS |
| WHAT AFFECT DOES BLOCKING THE INFLUX OF NA+ HAVE ON CONDUCTION | SLOWS IT DOWN |
| WHAT PHASE OF THE ACTION POTENTIAL DO GROUP-IA SODIUM CHANNEL BLOCKERS ACT | PHASE 0 |
| WHAT AFFECT DO GROUP I-A SODIUM CHANNEL BLOCKERS HAVE ON THE REFRACTORY PERIOD | PROLONGS IT |
| FOR WHAT CONDITIONS WOULD GROUP I-A SODIUM CHANNEL BLOCKERS BE USED | CHRONIC ATRIAL & VENTRICULAR TACHY-DYSRHYTHMIAS |
| WHAT ARE THE PROTOTYPES OF GROUP I-A SODIUM CHANNEL BLOCKERS | QUINIDINE AND PROCAINAMIDE |
| WHICH GROUP-IA SODIUM CHANNEL BLOCKER REQUIRES TELE MONITORING IF GIVEN VIA IV | PROCAINAMIDE |
| WHICH GROUP-IA SODIUM CHANNEL BLOCKER CONTAINS LESS GUANIDINE, QUINIDINE SULFATE OR QUINIDINE GLUCONATE | GLUCONATE |
| WHICH GROUP I-SODIUM CHANNEL BLOCKER IS THE DRUG OF CHOICE FOR UNSTABLE V-TACH | AMIODARONE |
| QUINIDINE IS RARELY GIVEN IV DUE TO WHAT | IT’S HYPOTENSIVE EFFECT |
| WHAT ARE THE TOXIC EFFECTS OF QUINIDINE | DIARRHEA, SYNCOPE |
| WHAT ARE THE TOXIC EFFECTS OF PROCAINAMIDE | LUPUS-LIKE SYNDROME-FEVER, RASH, SWOLLEN JOINTS |
| WHAT AFFECT DO QUINIDINE AND PROCAINAMIDE HAVE ON CARDIAC OUTPUT | MAY DECREASE |
| CINCHONISM MEANS WHAT | DYPLOPIA, HEADACH, TINNITUS |
| WHICH DRUG MAY CAUSE CINCHONISM | QUINIDINE GROUP I-A SODIUM CHANNEL BLOCKERS ACT HOW |
| WHAT PHASE OF THE ACTION POTENTIAL DO QUINIDINE AND PROCAINAMIDE AFFECT | PHASE 0 |
| AS A RESULT OF THE USE OF QUINIDINE AND PROCAINAMIDE CONDUCTION IS __________ | SLOWED |
| WHICH SODIUM CHANNEL BLOCKERS SLOW CONDUCTION AND PROLONG THE REFRACTORY PERIOD | QUINIDINE AND PROCAINAMIDE |
| WHAT IS ANOTHER PHRASE THAT MEANS ‘PROLONG THE REFRACTORY PERIOD’ | LENGTHENED ACTION POTENTIAL |
| ARE QUINIDINE AND/OR PROCAINAMIDE OK TO GIVE TO PATIENTS WITH CHF | NO |
| WHAT PROBLEM IN CHF WOULD BE WORSENED BY QUINIDINE AND/OR PROCAINAMIDE | DECREASED CARDIAC OUTPUT |
| WHAT IS THE PRIMARY USE OF QUINIDINE &/OR PROCAINAMIDE | CHRONIC ATRIAL &VENTRICULAR TACHY-DYSRRHYTHMIAS |
| WHAT ARE THE PROTOTYPES INCLUDED IN THE GROUP I-B SODIUM CHANNEL BLOCKERS? | LIDOCAINE AND TOCAINIDE |
| WHAT AFFECT DO GROUP I-B DRUGS HAVE ON THE REFRACTORY PERIOD | SHORTENS IT |
| LIDOCAINE AND TOCAINIDE ARE USED FOR | ACUTE, SYMPTOMATIC VENTRICULAR DYSRHTHMIAS |
| WHICH GROUP I SODIUM CHANNEL BLOCKER SUBGROUP PROLONGS THE REFRACTORY PERIOD | GROUP I-A |
| WHICH GROUP I SODIUM CHANNEL BLOCKER SUBGROUP SHORTENS THE REFRACTORY PERIOD | GROUP I-B |
| GROUP I-B SODIUM CHANNEL BLOCKERS SUPPRESS AUTOMATICITY, ESPECIALLY IN WHAT AREAS | THE BUNDLE AND PURKINJE SYSTEM |
| WHAT ARE THE PROTOTYPES IN GROUP I-B SODIUM CHANNEL BLOCKERS | LIDOCAINE AND TOCAINIDE |
| LIDOCAINE/XYLOCAINE MUST BE GIVEN WHAT ROUTE | IV |
| WHAT DRUG IS RESERVED FOR WHEN ALL OTHERS FAIL DUE TO IT’S POSSIBLE FATAL SIDE EFFECTS | TOCAINIDE/TONOCARD |
| TOCAINIDE/TONOCARD IS REFERRED TO AS | ORAL LIDOCAINE |
| THIS GROUP I SODIUM CHANNEL BLOCKER MUST BE GIVEN IV D/T IT’S RAPID ACTION | LIDOCAINE |
| SIDE EFFECTS OF LIDOCAINE INCLUDE | CONFUSION, LETHARGY |
| WHICH DRUGS SUPPRESS SUTOMATICITY IN THE BUNDLE AND PURKINJE SYSTEM | LIDOCAINE AND TOCAINIDE |
| GROUP I-A DRUGS PROLONG THE REFRACTORY PERIOD WHILE GROUP I-B DRUGS AFFECT THE REFRACTORY PERIOD HOW | SHORTEN IT |
| WHICH SODIUM CHANNEL BLOCKERS ARE USED FOR ACUTE, SYMPTOMATIC VENTRICULAR DYSRHYTHMIAS | LIDOCAINE AND TOCAINIDE |
| WHAT IS THE DRUG OF CHOICE FOR UNSTABLE V-TACH | AMIODARONE WHICH GROUP I SODIUM CHANNEL BLOCKERS HAVE NO EFFECT ON REFRACTORY PERIOD BUT MARKEDLY DEPRESS CONDUCTION |
| WHICH SUB GROUP OF SODIUM CHANNEL BLOCKERS SHORTEN THE REFRACTORY PERIOD | GROUP I-B WHAT DRUGS SHORTEN THE REFRACTORY PERIOD |
| GROUP I-C PROTOTYPE IS | FLECAINIDE ACETATE |
| FLECAINIDE IS USED FOR | LIFE-THREATENING VENTRICULAR DYSRHYTHMIAS |
| WHAT ARE THE SIDE EFFECTS OF FLECAINIDE | PROARRHYTHMIAS, CHF & BRADYCARDIA WHAT DRUG WORKS TO SUPPRESS AUTOMATICITY, ESPECIALLY IN THE BUNDLE AND PURKINJE SYSTEM |
| WHICH GROUP OS SODIUM CHANNEL BLOCKERS MAY CAUSE CONFUSION, LETHARGY | GROUP I-B, LIDOCAIN/TOCAINIDE WHICH GROUP OF SODIUM CHANNEL BLOCKERS MAY CAUSE A SHORTENED REFRACTORY PERIOD |
| WHICH SODIUM CHANNEL BLOCKERS ARE USED ONLY WHEN ALL OTHERS HAVE FAILED DUE TO POSSIBLE FATAL SIDE EFFECTS | TOCAINIDE |
| WHICH SODIUM CHANNEL BLOCKER HAS NO EFFECT ON REFRACTORY | FLECAINIDE ACETATE/TAMBOCOR |
| IF A PATIENT IS TAKING FLECAINIDE ACETATE/TAMBOCOR THEY SHOULD BE EDUCATED ON THE COMMON SIDE EFFECTS SUCH AS | PROARRHYTHMIAS, CHF, BRADYCARDIA |
| FOR LIFE-THREATENING VENTRICULAR DYSRHYTHMIAS WHAT WILL BE PRESCRIBED | FLECAINIDE/TAMBOCOR |
| FOR ACUTE DYSRTHYMIAS | GROUP I-B SODIUM CHANNEL BLOCKERS LIDOCAINE OR TOCAINIDE |
| WHAT IS THE DRUG OF CHOICE FOR UNSTABLE VENTRICULARY TACHYCARDIA | AMIODARONE |
| WHAT AFFECT DO GROUP I-B DRUGS HAVE ON THE REFRACTORY PERIOD | SHORTENS IT |
| LIDOCAINE AND TOCAINIDE ARE USED FOR | ACUTE, SYMPTOMATIC VENTRICULAR DYSRHTHMIAS |
| WHICH GROUP I SODIUM CHANNEL BLOCKER SUBGROUP PROLONGS THE REFRACTORY PERIOD | GROUP I-A |
| WHICH GROUP I SODIUM CHANNEL BLOCKER SUBGROUP SHORTENS THE REFRACTORY PERIOD | GROUP I-B |
| GROUP I-B SODIUM CHANNEL BLOCKERS SUPPRESS AUTOMATICITY, ESPECIALLY IN WHAT AREAS | THE BUNDLE AND PURKINJE SYSTEM |
| WHAT ARE THE PROTOTYPES IN GROUP I-B SODIUM CHANNEL BLOCKERS | LIDOCAINE AND TOCAINIDE |
| LIDOCAINE/XYLOCAINE MUST BE GIVEN WHAT ROUTE | IV |
| WHAT DRUG IS RESERVED FOR WHEN ALL OTHERS FAIL DUE TO IT’S POSSIBLE FATAL SIDE EFFECTS | TOCAINIDE/TONOCARD |
| TOCAINIDE/TONOCARD IS REFERRED TO AS | ORAL LIDOCAINE |
| THIS GROUP I SODIUM CHANNEL BLOCKER MUST BE GIVEN IV D/T IT’S RAPID ACTION | LIDOCAINE |
| SIDE EFFECTS OF LIDOCAINE INCLUDE | CONFUSION, LETHARGY |
| WHICH DRUGS SUPPRESS SUTOMATICITY IN THE BUNDLE AND PURKINJE SYSTEM | LIDOCAINE AND TOCAINIDE |
| GROUP I-A DRUGS PROLONG THE REFRACTORY PERIOD WHILE GROUP I-B DRUGS AFFECT THE REFRACTORY PERIOD HOW | SHORTEN IT |
| WHICH SODIUM CHANNEL BLOCKERS ARE USED FOR ACUTE, SYMPTOMATIC VENTRICULAR DYSRHYTHMIAS | LIDOCAINE AND TOCAINIDE |
| WHAT IS THE DRUG OF CHOICE FOR UNSTABLE V-TACH | AMIODARONE WHICH GROUP I SODIUM CHANNEL BLOCKERS HAVE NO EFFECT ON REFRACTORY PERIOD BUT MARKEDLY DEPRESS CONDUCTION |
| WHICH SUB GROUP OF SODIUM CHANNEL BLOCKERS SHORTEN THE REFRACTORY PERIOD | GROUP I-B WHAT DRUGS SHORTEN THE REFRACTORY PERIOD |
| GROUP I-C PROTOTYPE IS | FLECAINIDE ACETATE |
| FLECAINIDE IS USED FOR | LIFE-THREATENING VENTRICULAR DYSRHYTHMIAS |
| WHAT ARE THE SIDE EFFECTS OF FLECAINIDE | PROARRHYTHMIAS, CHF & BRADYCARDIA WHAT DRUG WORKS TO SUPPRESS AUTOMATICITY, ESPECIALLY IN THE BUNDLE AND PURKINJE SYSTEM |
| WHICH GROUP OS SODIUM CHANNEL BLOCKERS MAY CAUSE CONFUSION, LETHARGY | GROUP I-B, LIDOCAIN/TOCAINIDE WHICH GROUP OF SODIUM CHANNEL BLOCKERS MAY CAUSE A SHORTENED REFRACTORY PERIOD |
| WHICH SODIUM CHANNEL BLOCKERS ARE USED ONLY WHEN ALL OTHERS HAVE FAILED DUE TO POSSIBLE FATAL SIDE EFFECTS | TOCAINIDE |
| WHICH SODIUM CHANNEL BLOCKER HAS NO EFFECT ON REFRACTORY | FLECAINIDE ACETATE/TAMBOCOR |
| IF A PATIENT IS TAKING FLECAINIDE ACETATE/TAMBOCOR THEY SHOULD BE EDUCATED ON THE COMMON SIDE EFFECTS SUCH AS | PROARRHYTHMIAS, CHF, BRADYCARDIA |
| FOR LIFE-THREATENING VENTRICULAR DYSRHYTHMIAS WHAT WILL BE PRESCRIBED | FLECAINIDE/TAMBOCOR |
| FOR ACUTE DYSRTHYMIAS | GROUP I-B SODIUM CHANNEL BLOCKERS LIDOCAINE OR TOCAINIDE |
| WHAT IS THE DRUG OF CHOICE FOR UNSTABLE VENTRICULARY TACHYCARDIA | AMIODARONE |
| WHAT IS THE PROTOTYPE DRUG FOR GROUP II BETA-BLOCKERS? | PROPANOLOL (INDERAL) |
| IS PROPANOLOL A SELECTIVE OR NON-SELECTIVE BETA BLOCKER? | NON SELECTIVE |
| WHAT IS THE PROTOTYPE SELECTIVE BETA-BLOCKER? | METOPROLOL |
| WHICH TYPE OF BETA BLOCKER IS BEST FOR PULMONARY PATIENTS? | SELECTIVE |
| WOULD YOU GIVE METOPROLOL OR PROPANOLOL TO A COPD PATIENT? | METOPROLOL |
| A NON-SELECTIVE BLOCKS? | BOTH HEART AND LUNGS |
| A SELECTIVE BLOCKS | HEART |
| GROUP II BETA BLOCKERS HAVE WHAT ACTION? | DECREASE CONDUCTION, AUTOMATICITY, REFRACTORY PERIOD |
| GROUP II BETA BLOCKERS DO WHAT TO CONDUCTION, AUTOMATICITY AND THE REFRACTORY PERIOD? | SLOWS |
| BETA BLOCKERS ARE ____ INOTROPIC AND _____ CHRONOTROPIC | NEGATIVE INOTROPIC AND NEGATIVE CHRONOTROPIC |
| WHAT RISK IS THERE WHEN A DRUG IS BOTH NEGATIVE CHRONOTROPIC AND INOTROPIC? | CAN LEAD TO HEART FAILURE |
| BETA-BLOCKERS ARE USED FOR WHAT? | ATRIAL & VENTRICULAR DYSRHYTHMIAS |
| WHICH TWO GROUPS ARE USED FOR ATRIAL AND VENTRICULAR DYSRHYTHMIAS? | GROUP 1A SODIUM CHANNEL BLOCKERS AND GROUP II BETA BLOCKERS. |
| WHAT IS THE DIFFERENCE IN USE BETWEEN GROUP 1A AND GROUP II? | 1A IS FOR CHRONIC ATRIAL & VENTRICULAR TACHYDYSRHYTHMIAS AND BETA BLOCKERS ARE FOR ATRIAL AND VENTRICULAR DYSRHYTHMIAS. |
| WHICH GROUP TREATS CHRONIC ATRIAL AND VENTRICULAR TACHY-DYSRHYTHMIAS? | GROUP 1A SODIUM CHANNEL BLOCKERS |
| WHICH GROUP/GROUPS ARE USED FOR LIFE-THREATENING VENTRICULAR DYSRHYTHMIAS? | GROUP 1C & GROUP III POTASIUM BLOCKERS |
| WHICH DRUGS ARE USED FOR LIFE-THREATENING VENTRICULAR DYSRYTHMIAS? | FLECAINIDE AND AMIODARONE |
| BETA BLOCKERS MAY INFLUENCE ACTIVITY TOLERANCE HOW? | NEGATIVELY |
| IF A PERSON IS ON BETA BLOCKERS WHAT MIGHT A COMMON SIDE EFFECT BE? | ACTIVITY INTOLERANCE |
| PROPRANOLOL IS A | NON-SELECTIVE BETA BLOCKER |
| METOPROLOL IS A | SELECTIVE BETA BLOCKER |
| WHICH BETA BLOCKER CAN A COPD PATIENT TAKE? | METOPROLOL |
| THE GROUP III POTASSIUM CHANNEL BLOCKER PROTOTYPE IS | AMIODARONE |
| WHAT DRUG IS USED FOR UNSTABLE V-TACH? | AMIODARONE |
| WHAT ARE THE SIDE EFFECTS OF POTASSIUM CHANNEL BLOCKERS? | BRADYCARDIA, PULMONARY FIBROSIS AND CORNEAL MICRODEPOSITS. |
| AMIODARONE IS A DERIVITIVE OF? | THYROXINE |
| WHAT STUDIES MUST BE MONITORED FOR A PATIENT ON AMIODARONE? | THYROID LEVELS |
| WHAT DOES AMIODARONE DO TO REPOLARIZATION? | PROLONGS IT |
| WHAT PHASE(S) DOES AMIODARONE AFFECT? | PHASE 2 & 3, THE INFLUX OF POTASSIUM |
| GROUP IV CALCIUM CHANNEL BLOCKERS DECREASE | EXCITABILITY, CONTRACTILITY AND AUTOMATICITY |
| PSVT AND ATRIAL FLUTTER/FIB ARE TREATED WITH WHAT GROUP OF DRUGS? | GROUP IV: CALCIUM CHANNEL BLOCKERS |
| CALCIUM CHANNEL BLOCKERS SLOW THE ATRIAL OR VENTRICULAR RATE? | VENTRICULAR |
| WHAT IS THE PROTOTYPE DRUG IN GROUP IV CALCIUM CHANNEL BLOCKERS? | VERAPAMIL |
| WHAT CALCIUM CHANNEL BLOCKER IS BEST FOR DYSRHYTHMIAS? | VERAPAMIL |
| WHAT CALCIUM CHANNEL BLOCKER IS BEST FOR ANGINA? | DILTIAZEM (CARDIZEM) |
| WHAT CALCIUM CHANNEL BLOCKER IS THE BEST AS A VASODILATOR FOR REDUCING AFTERLOAD? | NIFEDIPINE (PROCARDIA) |
| NIFEDIPIINE IS BEST FOR REDUCING? | AFTERLOAD |
| WHAT CALCIUM CHANNEL BLOCKER CAN CAUSE DIG TOXICITY? | VERAPAMIL |
| BETA BLOCKERS ARE FOR | ATRIAL AND VENTRICULAR DYSRHYTHMIAS |
| POTASSIUM CHANNEL BLOCKERS ARE FOR | LIFE THREATENING VENTRICULARY DYSRHYTHMIAS |
| BRADYCARDIA, CHF AND DIG TOXICITY ARE SIDE EFFECTS OF | CALCIUM CHANNEL BLOCKERS |
| WHAT ARE THE THREE CALCIUM CHANNEL BLOCKERS USED FOR DYSRHYTHMIAS? | VERAPAMIL, DILTIAZEM AND NIFEDIPDINE |
| NIFEDIPINE | VASODILATOR, REDUCES AFTERLOAD |
| DILTIAZEM | ANGINA |
| ANGINA | DILTIAZEM |
| REDUCE AFTERLOAD WITH | NIFEDIPINE |
| WHAT IS THE PROTOTYPE GROUP IV CALCIUM CHANNEL BLOCKER? | VERAPAMIL |
| ATROPINE IS AN | ANTICHOLINERGIC |
| ATROPINE HAS WHAT EFFECT ON HEART RATE | INCREASES IT |
| WHAT IS ATROPINE USED FOR | SYMPTOMATIC BRADYCARDIA |
| EPINEPHRINE IS A | CATECHOLAMINE |
| EPINEPHRINE DOES WHAT TO CONTRACTIONS | STRENGTHENS |
| WHAT BENEFIT DOES EPINEPHRINE HAVE FOR BP SUPPORT? | ELEVATES IT |
| MAG SULFATE REDUCES THE | EXCITABILITY OF CARDIAC CELLS |
| WHAT MED IS USED FOR DIGITALIS-INDUCED DYSRHYTHMIAS AND TORSADES? | MAG SULFATE |
| TORSADES IS TREATED WITH | MAG SULFATE |
| DIGITALIS INDUCED DYSRHYTHMIAS IS TREATED WITH | MAG SULFATE |
| VASOPRESSIN IS USED FOR | CARDIOGENIC SHOCK |
| GROUP IA TREATS | CHRONIC A&V TACHY |
| GROUP IB TREATS | ACUTE SYMPTOMATIC VENTRICULAR DYSR |
| GROUP IC TREATS | `LIFE THREATENING VENTRICULAR DYSRH |
| GROUP II BETA BLOCKERS TREAT | ATRIAL AND VENTRICULAR DYSRHYTHMIAS |
| GROUP III POTASSIUM CHANNEL BLOCKERS TREAT | LIFE THREATENING VENTRICULAR DYSRH |
| GROUOP IV CALCIUM CHANNEL BLOCKERS TREAT | PSVT, ATRIAL FLUTTER/FIB TO SLOW VENT RATE |
| WHICH GROUP SLOWS VENTRICULAR RATE? | GROUP IV CALCIUM CHANNEL BLOCKERS |
| ATRIAL & VENTRICULAR TACHY DYSRHYTHMIAS ARE TREATED WITH | GROUP IA SODIUM CHANNEL BLOCKERS |